# Pralatrexate and Docetaxel in Treating Patients With Stage IV Esophageal or Gastroesophageal Cancer Who Have Failed Platinum-Based Therapy

> **NCT01129206** · PHASE2 · COMPLETED · sponsor: **Ohio State University Comprehensive Cancer Center** · enrollment: 6 (actual)

## Conditions studied

- Adenocarcinoma of the Esophagus
- Adenocarcinomas of the Gastroesophageal Junction
- Recurrent Esophageal Cancer
- Squamous Cell Carcinoma of the Esophagus
- Stage IV Esophageal Cancer

## Interventions

- **DRUG:** pralatrexate
- **DRUG:** docetaxel
- **RADIATION:** fludeoxyglucose F 18
- **PROCEDURE:** positron emission tomography

## Key facts

- **NCT ID:** NCT01129206
- **Lead sponsor:** Ohio State University Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2012-09
- **Final completion:** —
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2016-06-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01129206

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01129206, "Pralatrexate and Docetaxel in Treating Patients With Stage IV Esophageal or Gastroesophageal Cancer Who Have Failed Platinum-Based Therapy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01129206. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*